Phase i study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Cyclin-Dependent Kinases
  • Neoplasms
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Quinazolines
  • Receptor, trkA

abstract

  • The RP2D of PHA-848125AC was 150 mg/day on both schedules. Based on the responses noted in thymic carcinoma, a phase II study for patients with that disease is currently enrolling.

publication date

  • December 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3561458

Digital Object Identifier (DOI)

  • 10.1007/s10637-011-9774-6

PubMed ID

  • 22160853

Additional Document Info

start page

  • 2334

end page

  • 43

volume

  • 30

number

  • 6